Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

ImmuPharma

Ownership
Private
Employees
~35
Therapeutic Areas
ImmunologyNeurologyInfectious Diseases
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Peptide therapeutics(Reformulated) small molecules

ImmuPharma General Information

AIM-listed biopharmaceutical company developing peptide-based therapies and reformulated anti-infectives, with lead candidate P140 in Phase3 for SLE and Phase2/3 for CIDP. Proprietary ADMET technology enhances drug properties.

Contact Information

Website
https://www.immupharma.co.uk/
Primary Industry
Biotech
Corporate Office
London,
UK

Drug Pipeline

P140 (Lupuzor)
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ImmuPharma's pipeline data

Book a demo

Key Partnerships

[object Object], [object Object], [object Object]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ImmuPharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ImmuPharma's complete valuation and funding history, request access »

ImmuPharma Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals